Search Results
Results 1-10 of 13 of “CDIB CAPITAL HEALTHCARE VENTURES”
long-acting release drug products for opioid use disorder, chronic pain, and major depressive disorder. Taiwan. 2016. Stemchymal® allogeneic stem cells products. USA. 2018. Immunotherapies for cancer with myeloid checkpoint inhibitors. Taiwan.
Venture and Growth Capital. Overview. Strategies . Overview. ... Healthcare Strategies . We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors. ... primarily in North America and Asia Pacific. We also invest across the ...
Venture capital and private equity investments in life sciences and healthcare in the Asia-Pacific region (Johnson & Johnson Development Corporation (JJDC)) 2013-19. Joined CDIB in 2019. Expertise in M&A and Investment Transactions
CDF reports April after-tax profit of NT$2.42 billion. After-tax profit for the first four months reached NT$10.63 billion, and EPS was NT$0.64. China Development Financial Holding Corporation (hereinafter referred to as "CDF") reported today its profit for the month of April.
About Us. Founded in 1959, we have become a leading equity investment and asset management brand in Asia along the way. learn more.
Aosheng hi-tech is a leading manufacturer of high-performance composite materials such as carbon fiber and prepreg. Its products are used in wind turbine blade, construction, consumer electronics, healthcare and sporting goods. The company has 15 year of experience in the carbon fiber industry in China.
Gary is a Managing Director of CDIB Capital International based in Hong Kong. With 22 years of experience in private equity, he has deep knowledge of the asset class and currently oversees the fund investment portfolio for China Life Insurance. He also leads a team that provides investment advisory services on private equity fund investments ...
He oversees CDIB's overall strategy, executive management, and day-to-day operations with a total third party and proprietary AUM of ~US$2.5 billion. Lionel has also played a critical role in CDF's exponential growth from total assets of approximately NT$270 billion in 2006 to NT$3.5 trillion in 2021. Amongst other things, he has driven group ...
Prior to joining CDIB Capital Group, Mr. Koo became President of KGI Securities (Taiwan) in 1996 and established KGI Securities (Hong Kong) in 1997, and within eight years (1996-2004), KGI Securities’ market capitalization had grown rapidly by around seven times and asset size by over 20 times, while also successfully bringing to completion the daunting challenge of integrating KGI ...
With an industry-leading international team, we play a pivotal leading role in Taiwan's venture capital and private equity markets This website uses cookies to offer you the best services. By continuing to browse or by clicking Accept, you agree to the storing of cookies on your device for the optimal experience.